Zenitar's Organoid Screening Platform, adopting a "from clinic to clinic" approach, has established a proprietary organoid culture system for solid tumors. This platform is designed to enable efficient and precise personalized drug screening and targeted therapy development. Ultimately, it aims to develop drug screening systems and treatment strategies with significant clinical application potential.